The AJMC® Multiple Myeloma compendium is a comprehensive resource for clinical news and expert insights for this cancer.
April 23rd 2024
The FDA granted accelerated approval to talquetamab on August 9, 2023, as a treatment option for adult patients with relapsed/refractory multiple myeloma (RRMM) who have failed at least 4 prior lines of therapy.
Levels of Certain Thyroid Hormone May Help With Risk Stratification in MM
May 4th 2022With survival of multiple myeloma ranging from less than 1 month to over 10 years, the researchers highlighted the importance of risk stratification to quickly identify patients who are high risk with poor prognosis and could benefit from different treatment strategies and close surveillance.
Read More
Mesenchymal Stem Cells Induce Cell Proliferation, Inhibit Dexamethasone Effectiveness in MM
April 22nd 2022Mesenchymal stem cells are known to promote tumor growth and metastasis in multiple myeloma (MM), but a recent study found they may also inhibit the effects of the corticosteroid dexamethasone, a common medication for the hematologic malignancy.
Read More
Higher Risk of CV Mortality Seen in Patients With MM Compared With General Population
April 14th 2022While studies have explored risks among patients with multiple myeloma, recent research is the first to compare cardiovascular mortality risk in multiple myeloma to that of the general population.
Read More
New Minimal Residual Disease Assessment Could Detect Disease Progression Earlier in MM
April 11th 2022Flow–minimal residual disease (MRD) assessment in patients with multiple myeloma (MM) was found to be a good tool for early detection of MRD and could aid providers in treatment decision-making.
Read More
Obesity Increases Risk of MM Precursor, While Weight Loss Indicates Risk of Cancer Diagnosis
March 25th 2022Weight and changes in it can indicate implications for cancer risk and cancer diagnosis, according to 2 abstracts being presented at the American Association for Cancer Research Annual Meeting.
Read More
New Risk Prediction Model for MM Outcomes Found Easy to Use, Implement in Clinical Practice
March 22nd 2022A new frailty-based outcome prediction model for multiple myeloma (MM) was found to be an easy-to-use tool in clinical practice and produced valid results based on a large real world cohort of patients with a new MM diagnosis, according to a recent study.
Read More
Multi-Tiered Risk Stratification Model for MM May Perform Better Than Standard Systems
March 18th 2022Risk stratification is a difficult process for multiple myeloma (MM), and authors concluded that their multi-tiered model may provide a greater risk assessment benefit than standard stratification systems.
Read More
MM and Regimens for First- and Second-Line Treatment
March 15th 2022Joshua Richter, MD, and Roy Beveridge, MD, explain the role triplet regimens play in MM treatment and how physician decision-making has been impacted since the NCCN guidelines have expanded the list of acceptable first- and second-line treatment options.
Watch
Addressing Low Vitamin D Levels May Reduce Risk of Peripheral Neuropathy in MM
March 11th 2022Researchers found that low levels of vitamin D and the prevalence of peripheral neuropathy were common in patients with multiple myeloma, suggesting that addressing the former could help prevent the latter.
Read More
Study Finds Decorin May Have Protective Effect in Multiple Myeloma
March 8th 2022Decorin, a highly conserved, class 1 small leucine-rich repeat proteoglycan expressed in the extracellular matrix, may have a protective effect in a subset of patients with multiple myeloma, investigators concluded.
Read More